Chinese authorities approve seasoned Novo Nordisk combination treatment

A 2022 New Year's resolution for Novo Nordisk will be to launch the combination treatment type 2 diabetes, Xultophy, in China, a goal made possible by the national authority's approval of the seven-year-old drug.

The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading